{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:19:03Z","timestamp":1780481943792,"version":"3.54.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A systematic search was performed in 3 databases (Pubmed, Embase, and Cochrane Library) for articles evaluating the effectiveness and safety of GLP-1RAs (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) for the treatment of obese patients with CHF from the time the database was created until 5 January 2025. Meta-analyses were performed to evaluate: primary outcomes, including all-cause mortality, cardiovascular mortality, and worsening heart failure events; secondary outcomes, encompassing changes in body weight, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), 6-minute walk distance, B-type Natriuretic Peptide (BNP) level, high-sensitivity C-Reactive Protein (hs-CRP) level, and left ventricular ejection fraction (LVEF) level; and safety outcomes, specifically gastrointestinal adverse events and serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 6 papers were included for Meta-analysis. The primary clinical outcomes: all-cause mortality [OR=0.89, 95% confidence interval (CI): 0.40\u20132.00, <jats:italic>p<\/jats:italic>\u2009=\u20090.78], cardiovascular mortality (OR\u2009=\u20090.93, 95% CI: 0.22\u20134.00, <jats:italic>p<\/jats:italic>\u2009=\u20090.92) and worsening heart failure events (OR=0.43, 95% CI: 0.30\u20130.59, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001); For secondary outcomes, change in body weight (MD\u2009=\u2009\u22127.90, 95% CI: \u221215.44 to \u22120.35, <jats:italic>p<\/jats:italic>\u2009=\u20090.04), change in the KCCQ-CSS (MD\u2009=\u20096.81, 95% CI: 6.62\u20136.99, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001),change in the 6-minute walk distance (MD\u2009=\u200915.91, 95% CI: 15.36\u201316.47, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001), change in the BNP level (MD\u2009=\u2009\u22120.13, 95% CI: \u22120.21 to \u22120.05, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), changes in the hs-CRP level (MD\u2009=\u2009\u221216.61, 95% CI: \u221248.53 to 15.31, <jats:italic>p<\/jats:italic>\u2009=\u20090.31) and change in the LVEF level (MD\u2009=\u2009\u22120.91, 95% CI: \u22122.12 to 0.29, <jats:italic>p<\/jats:italic>\u2009=\u20090.14). For safety outcomes, gastrointestinal adverse events (OR=0.87, 95% CI: 0.11\u20137.05, <jats:italic>p<\/jats:italic>\u2009=\u20090.90) and serious adverse events (OR=0.63, 95% CI: 0.37\u20131.08, <jats:italic>p<\/jats:italic>\u2009=\u20090.09).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study results show that GLP-1RAs significantly reduce the risk of worsening heart failure events and improve cardiac function, suggesting that GLP-1RAs are promising treatment options for obese patients with CHF.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1633114","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:51:03Z","timestamp":1759503063000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Anna","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusi","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.7748\/ns.2023.e12049","article-title":"An overview of chronic heart failure","volume":"38","author":"Shrestha","year":"2023","journal-title":"Nurs Stand"},{"key":"B2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cnur.2015.07.012","article-title":"Heart failure: pathophysiology, diagnosis, medical treatment guidelines, and nursing management","volume":"50","author":"Rogers","year":"2015","journal-title":"Nurs Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pcad.2024.01.003","article-title":"Update on obesity, the obesity paradox, and obesity management in heart failure","volume":"82","author":"Alebna","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction","volume":"30","author":"Bonfioli","year":"2025","journal-title":"Heart Fail Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"132304","DOI":"10.1016\/j.ijcard.2024.132304","article-title":"Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies","volume":"412","author":"Abdin","year":"2024","journal-title":"Int J Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e010618","DOI":"10.1161\/CIRCHEARTFAILURE.123.010618","article-title":"Obesity-related biomarkers are associated with exercise intolerance and HFpEF","volume":"16","author":"Ramirez","year":"2023","journal-title":"Circ Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","article-title":"User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer","year":"2015","journal-title":"Postgrad Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","article-title":"The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials","volume":"118","author":"Liu","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-025-02607-w","article-title":"The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)","volume":"24","author":"Hullon","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10557-022-07360-w","article-title":"Effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cardiac structure and function: a systematic review and meta-analysis of randomized-controlled trials","volume":"38","author":"Wong","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinthera.2022.12.006","article-title":"Effect of glucagon-like peptide-1 receptor agonists on prognosis of heart failure and cardiac function: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Huixing","year":"2023","journal-title":"Clin Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24875\/ACM.M24000095","article-title":"Clinical practice guidelines for diagnostic and treatment of the chronic heart failure","volume":"94","author":"Pav\u00eda-L\u00f3pez","year":"2024","journal-title":"Arch Cardiol Mex"},{"key":"B18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program","volume":"84","author":"Schou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fendo.2017.00325","article-title":"Effects on subclinical heart failure in type 2 diabetic subjects on liraglutide treatment vs. glimepiride both in combination with metformin: a randomized open parallel-group study","volume":"8","author":"Nystr\u00f6m","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2174\/1573399813666170414101450","article-title":"Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: a meta-analysis","volume":"14","author":"Peterson","year":"2018","journal-title":"Curr Diabetes Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00125-023-06057-5","article-title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study","volume":"67","author":"Krishnan","year":"2024","journal-title":"Diabetologia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101218","DOI":"10.1016\/j.ijcha.2023.101218","article-title":"Effects of GLP-1 agonists on mortality and arrhythmias in patients with type II diabetes","volume":"47","author":"Al-Sadawi","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1111\/dom.15185","article-title":"All-cause mortality and cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes","volume":"25","author":"Riley","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1244432","DOI":"10.3389\/fendo.2023.1244432","article-title":"Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review","volume":"14","author":"Xie","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e40364","DOI":"10.1097\/MD.0000000000040364","article-title":"Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: a review","volume":"103","author":"Raza","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ehf2.14560","article-title":"Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists","volume":"11","author":"Cimino","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jacc.2024.04.064","article-title":"Liraglutide improves myocardial perfusion and energetics and exercise tolerance in patients with type 2 diabetes","volume":"84","author":"Chowdhary","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-8587(24)00304-8","article-title":"Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial","volume":"13","author":"Davies","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijcard.2022.03.032","article-title":"The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis","volume":"357","author":"Avogaro","year":"2022","journal-title":"Int J Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jdiacomp.2016.05.022","article-title":"Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Mazidi","year":"2017","journal-title":"J Diabetes Complications"},{"key":"B39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12933-024-02415-8","article-title":"Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis","volume":"23","author":"Albulushi","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"62693","DOI":"10.18632\/oncotarget.18570","article-title":"Effects of liraglutide on hemodynamic parameters in patients with heart failure","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1007\/s00125-024-06144-1","article-title":"Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials","volume":"67","author":"Karagiannis","year":"2024","journal-title":"Diabetologia"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1633114\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:51:05Z","timestamp":1759503065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1633114\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":42,"alternative-id":["10.3389\/fcvm.2025.1633114"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1633114","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"article-number":"1633114"}}